Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by JPL Wealth Management LLC

JPL Wealth Management LLC lessened its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 10.0% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The firm owned 31,429 shares of the biopharmaceutical company's stock after selling 3,483 shares during the quarter. Gilead Sciences makes up 1.4% of JPL Wealth Management LLC's holdings, making the stock its 21st biggest position. JPL Wealth Management LLC's holdings in Gilead Sciences were worth $3,522,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in GILD. Madison Asset Management LLC grew its position in shares of Gilead Sciences by 20.0% in the first quarter. Madison Asset Management LLC now owns 4,800 shares of the biopharmaceutical company's stock valued at $538,000 after purchasing an additional 800 shares during the period. Venturi Wealth Management LLC boosted its position in Gilead Sciences by 7.3% during the first quarter. Venturi Wealth Management LLC now owns 2,852 shares of the biopharmaceutical company's stock worth $320,000 after acquiring an additional 194 shares during the last quarter. SYM FINANCIAL Corp acquired a new position in Gilead Sciences during the first quarter worth about $213,000. Beacon Investment Advisory Services Inc. boosted its position in Gilead Sciences by 8.0% during the first quarter. Beacon Investment Advisory Services Inc. now owns 86,661 shares of the biopharmaceutical company's stock worth $9,710,000 after acquiring an additional 6,429 shares during the last quarter. Finally, Proficio Capital Partners LLC boosted its position in Gilead Sciences by 10.0% during the first quarter. Proficio Capital Partners LLC now owns 4,043 shares of the biopharmaceutical company's stock worth $453,000 after acquiring an additional 368 shares during the last quarter. Institutional investors and hedge funds own 83.67% of the company's stock.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on the stock. Cantor Fitzgerald assumed coverage on shares of Gilead Sciences in a research report on Tuesday, April 22nd. They set an "overweight" rating and a $125.00 price target on the stock. Needham & Company LLC raised shares of Gilead Sciences from a "hold" rating to a "buy" rating and set a $133.00 price target on the stock in a research note on Friday. Morgan Stanley upped their target price on shares of Gilead Sciences from $130.00 to $135.00 and gave the stock an "overweight" rating in a research note on Friday, April 25th. Finally, Oppenheimer dropped their price objective on shares of Gilead Sciences from $132.00 to $125.00 and set an "outperform" rating on the stock in a research report on Friday, April 25th. Eight investment analysts have rated the stock with a hold rating, fifteen have issued a buy rating and three have issued a strong buy rating to the stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $112.36.

Insider Activity at Gilead Sciences

In other Gilead Sciences news, insider Johanna Mercier sold 3,000 shares of Gilead Sciences stock in a transaction on Tuesday, July 15th. The shares were sold at an average price of $111.03, for a total value of $333,090.00. Following the completion of the transaction, the insider owned 117,168 shares of the company's stock, valued at $13,009,163.04. The trade was a 2.50% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, Director Jeffrey Bluestone sold 5,000 shares of Gilead Sciences stock in a transaction on Monday, July 14th. The stock was sold at an average price of $109.74, for a total transaction of $548,700.00. Following the completion of the transaction, the director directly owned 8,920 shares of the company's stock, valued at approximately $978,880.80. This represents a 35.92% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 72,000 shares of company stock worth $7,844,775 in the last ninety days. 0.27% of the stock is currently owned by corporate insiders.

Gilead Sciences Trading Up 2.7%

Shares of GILD traded up $3.00 during mid-day trading on Friday, hitting $116.20. The company had a trading volume of 7,677,220 shares, compared to its average volume of 5,825,949. The stock has a market cap of $144.54 billion, a PE ratio of 24.46, a P/E/G ratio of 0.72 and a beta of 0.29. The company has a quick ratio of 1.23, a current ratio of 1.37 and a debt-to-equity ratio of 1.16. Gilead Sciences, Inc. has a 1-year low of $72.43 and a 1-year high of $119.96. The business's 50-day simple moving average is $109.91 and its 200-day simple moving average is $105.88.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.77 by $0.04. The company had revenue of $6.67 billion for the quarter, compared to analyst estimates of $6.77 billion. Gilead Sciences had a net margin of 20.76% and a return on equity of 51.93%. The business's quarterly revenue was down .3% on a year-over-year basis. During the same quarter last year, the firm posted ($1.32) earnings per share. Sell-side analysts forecast that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.